Welcome to our dedicated page for Intelligent Bio Solutions SEC filings (Ticker: INBS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Intelligent Bio Solutions Inc. (INBS) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed medical technology issuer, Intelligent Bio Solutions uses these filings to report financial results, corporate actions, governance matters and material events related to its non-invasive drug screening and testing solutions.
Investors researching INBS can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of the company’s business, risk factors, financial statements and segment information. These periodic reports describe the Intelligent Fingerprinting Drug Screening System, the company’s consumables-focused revenue model, geographic reach and customer segments in sectors such as construction, manufacturing and engineering, transport and logistics, mining, drug treatment organizations and coroners.
The company also files numerous Form 8-K current reports covering specific developments. Recent 8-K filings describe preliminary and final revenue results, record quarterly revenue driven by cartridge sales, the extension of warrant termination dates, new customer account additions, and updates on regulatory timelines for FDA 510(k) clearance of the Intelligent Fingerprinting Drug Screening System. Other 8-Ks detail stockholder meeting outcomes, amendments to the 2019 Long Term Incentive Plan, and the approval and implementation of a 1-for-10 reverse stock split effective December 15, 2025.
Listing-related disclosures appear in filings that discuss Nasdaq bid price compliance, including the December 15, 2025 deficiency letter noting that the company’s closing bid price had been below $1.00 per share for 30 consecutive business days and granting an initial 180-day compliance period. Additional filings describe equity and warrant transactions, such as private placements and warrant inducement arrangements submitted for stockholder approval under Nasdaq rules.
On Stock Titan, these documents are supplemented with AI-powered summaries that highlight key points from lengthy 10-K, 10-Q and 8-K filings, helping readers quickly understand topics like revenue trends, capital structure changes, equity incentive plan amendments and regulatory updates. Users can also locate information relevant to insider and equity-linked activity by reviewing warrant-related disclosures and stock-based compensation plans discussed in proxy statements and current reports.
By using this INBS filings page, investors and analysts can efficiently monitor how Intelligent Bio Solutions communicates its financial condition, strategic initiatives, governance decisions and listing status to regulators and the market, without needing to manually parse each full-length SEC document.
Intelligent Bio Solutions Inc. granted new restricted stock awards and reported an update on its at-the-market (ATM) offering capacity. On March 18, 2026, the CEO and CFO each received 9,150 time-vesting shares and 21,350 performance-vesting shares under the 2019 Long Term Incentive Plan, with multi-year vesting tied to clinical, FDA submission, and commercial milestones and a ten-year deadline for meeting performance goals.
Non-employee directors received an aggregate 20,000 time-vesting shares, while non-executive employees received 10,500 time-vesting and 24,500 performance-vesting shares. The company stated that total common shares outstanding were 2,001,173 as of March 23, 2026. It also filed a 2026 ATM prospectus supplement, allowing sales of additional common stock with an aggregate gross sales price of up to $3,966,316 under its existing Form S-3 shelf and ATM agreement.
Intelligent Bio Solutions, Inc. is offering up to $3,966,316 of common stock through an at-the-market program with Ladenburg Thalmann & Co. Inc., allowing sales from time to time on Nasdaq or other U.S. trading markets. The supplement states $3,966,316 remains available under the ATM Agreement.
The supplement reports a public float of $18,572,023 based on March 23, 2026 data and 1,910,702 shares held by non-affiliates, and a last sale price of $3.43 per share on March 20, 2026. Proceeds are intended for working capital and general corporate purposes. The filing discloses substantial doubt about the company’s ability to continue as a going concern, citing cash and receivable balances and the need for additional financing.
Boyages Steven Constantine reported acquisition or exercise transactions in this Form 4 filing.
INTELLIGENT BIO SOLUTIONS INC. director Steven Constantine Boyages received a grant of 5,000 restricted shares of Common Stock on March 18, 2026 under the company’s 2019 Long Term Incentive Plan. These shares vest after 12 months and may be forfeited if vesting conditions are not met. Following this equity award, Boyages holds 5,031 common shares directly. All amounts are presented on a post–1-for-10 reverse stock split basis after the company’s December 15, 2025 reverse split.
Fraser Nicola Marion reported acquisition or exercise transactions in this Form 4 filing.
INTELLIGENT BIO SOLUTIONS INC. director Fraser Nicola Marion received an equity award rather than conducting an open‑market trade. On March 18, 2026, the company granted him 5,000 restricted shares of Common Stock under its 2019 Long Term Incentive Plan, at no cash purchase price.
The restricted shares vest based on time after 12 months and may be forfeited if vesting conditions are not met. Following this grant, Marion holds 5,000 shares of Common Stock directly, with all amounts presented on a post‑reverse‑split basis after the company’s prior reverse stock splits.
Sakiris Spiro Kevin reported acquisition or exercise transactions in this Form 4 filing.
INTELLIGENT BIO SOLUTIONS INC. Chief Financial Officer Kevin Sakiris received equity awards in the form of common stock. On March 18, 2026, he was granted 9,150 restricted shares that vest over 48 months and 21,350 restricted shares subject to both performance-based and time-based vesting, all under the 2019 Long Term Incentive Plan.
Following these compensation grants, Sakiris directly holds 33,981 shares of common stock and indirectly holds 1,911 shares through Anest Holdings Pty Ltd, as trustee of the S&T Sakiris Superannuation Fund. All share amounts are presented after a prior 1-for-10 reverse stock split.
Hurd Jonathan Scott reported acquisition or exercise transactions in this Form 4 filing.
INTELLIGENT BIO SOLUTIONS INC. director Jonathan Scott Hurd received a grant of 5,000 restricted shares of Common Stock on March 18, 2026 under the company’s 2019 Long Term Incentive Plan. The shares vest after 12 months and can be forfeited until vested. Following this award, he holds 5,006 shares directly, with all amounts presented after a 1-for-10 reverse stock split effected on December 15, 2025.
Isenberg Jason reported acquisition or exercise transactions in this Form 4 filing.
INTELLIGENT BIO SOLUTIONS INC. director Jason Isenberg reported an equity award of 5,000 shares of Common Stock. The shares were granted on March 18, 2026 under the company’s 2019 Long Term Incentive Plan at no cash cost and are his entire reported direct holding of 5,000 shares.
The 5,000 shares are restricted stock that vest after 12 months and are subject to forfeiture until they vest. All share amounts are presented on a post–1-for-10 reverse stock split basis reflecting the reverse split effected on December 15, 2025 and earlier reverse splits.
Simeonidis Harry reported acquisition or exercise transactions in this Form 4 filing.
Intelligent Bio Solutions Inc. granted Chief Executive Officer Harry Simeonidis new equity awards in the form of restricted common stock. On March 18, 2026, he received 9,150 restricted shares that vest over 48 months, and 21,350 additional restricted shares subject to both performance-based and time-based vesting conditions. These awards were issued at no cash cost under the company’s 2019 Long Term Incentive Plan and are subject to forfeiture until the vesting requirements are met. All share amounts reflect prior reverse stock splits, including a 1-for-10 split effective December 15, 2025.
Intelligent Bio Solutions Inc. announced that it has received and deployed the first shipment of its Intelligent Fingerprinting Drug Screening Readers manufactured by new partner Syrma Johari MedTech Ltd. This confirms that the strategic manufacturing partnership, first announced in December 2025, is operating as planned.
The readers, produced to ISO 13485 and MDSAP standards, are being rolled out across construction, transportation, logistics, and manufacturing customers in the U.K. and Europe, expanding the installed base ahead of planned U.S. market entry in 2026. The partnership provides access to manufacturing capacity about four times prior levels and is expected to deliver annual production cost savings of more than 40%, supporting an anticipated improvement of roughly 20 percentage points in gross margin.
The company has also doubled in-house production capacity for its lateral flow test strips, giving it greater control over critical components, faster innovation cycles, and the ability to develop cartridges with additional test lines for expanded drug panels.
Intelligent Bio Solutions Inc. reported strong growth for its fiscal second quarter ended December 31, 2025, while remaining loss-making. Revenue rose to $896,774, a 48% year-over-year increase, driven by reader sales of $246,519 (up 104%) and cartridge sales of $516,754 (up 33%).
For the first half of fiscal 2026, revenue reached $2.01 million, up 36% year-over-year, with gross profit margins improving to 49% from 39%. Despite this, the company recorded a net loss of $2.68 million for the quarter and $5.66 million for the six months.
The company closed a $10.0 million private placement with healthcare-focused institutional investors, generating $9.40 million in net proceeds received on January 2, 2026, to support working capital, its FDA 510(k) submission, and international expansion. As of December 31, 2025, total assets were $17.65 million and shareholders’ equity was $10.89 million.